Cargando…

Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study

BACKGROUND: Tumor mutation burden (TMB) is an emerging prognostic biomarker of immunotherapy for bladder cancer (BLCA). We aim at investigating radiomic features’ value in predicting the TMB status of BLCA patients. METHODS: Totally, 75 patients with BLCA were enrolled. Radiomic features extracted f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xin, Qian, Wen-lei, Yan, Wei-feng, Pang, Tong, Gong, You-ling, Yang, Zhi-gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285848/ https://www.ncbi.nlm.nih.gov/pubmed/34271855 http://dx.doi.org/10.1186/s12885-021-08569-y

Ejemplares similares

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

ecTMB: a robust method to estimate and classify tumor mutational burden
por: Yao, Lijing, et al.
Publicado: (2020)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
por: Cui, Shengjin, et al.
Publicado: (2023)

Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications
por: Saeed, Anwaar, et al.
Publicado: (2020)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
por: Tang, Xin, et al.
Publicado: (2021)

The Prognostic Value of Radiomics Features Extracted From Computed Tomography in Patients With Localized Clear Cell Renal Cell Carcinoma After Nephrectomy
por: Tang, Xin, et al.
Publicado: (2021)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy
por: Li, Xiangmei, et al.
Publicado: (2023)

Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients
por: Yan, Dan, et al.
Publicado: (2021)

Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing
por: Yu, Yongfeng, et al.
Publicado: (2021)

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
por: Qiu, Ping, et al.
Publicado: (2019)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
por: Palmeri, M., et al.
Publicado: (2021)

The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Nan, Zhang, et al.
Publicado: (2021)

Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)
por: Ma, Xiaoting, et al.
Publicado: (2021)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014
por: Munk, Niki, et al.
Publicado: (2016)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
por: Fridland, Stanislav, et al.
Publicado: (2021)

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB(2) harmonization project comparing three NGS panels
por: Ramos-Paradas, Javier, et al.
Publicado: (2021)

A novel prognostic model predicting the long-term cancer-specific survival for patients with hypopharyngeal squamous cell carcinoma
por: Tang, Xin, et al.
Publicado: (2020)

Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images
por: Qian, Jing, et al.
Publicado: (2022)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer
por: Cheng, Yanan, et al.
Publicado: (2022)

The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients
por: Yang, Ying, et al.
Publicado: (2022)

Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma
por: Gu, Weiquan, et al.
Publicado: (2020)

Intratumor heterogeneity of driver mutations and TMB distribution in 30 early-stage LUAD patients with multiple lesions
por: Qiu, Yuan, et al.
Publicado: (2022)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

Predicting Tumor Mutation Burden and EGFR Mutation Using Clinical and Radiomic Features in Patients with Malignant Pulmonary Nodules
por: Yin, Wenda, et al.
Publicado: (2022)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
por: Hodi, F. Stephen, et al.
Publicado: (2021)

Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis
por: Ma, Yao, et al.
Publicado: (2019)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC
por: Křížová, Ľudmila, et al.
Publicado: (2022)

Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers
por: Tan, Qing, et al.
Publicado: (2023)

Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB
por: Miao, Xia-ye, et al.
Publicado: (2022)

TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment
por: Li, Huahua, et al.
Publicado: (2020)

MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method
por: Li, Zhengtian, et al.
Publicado: (2021)

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients
por: Zhu, Gongmin, et al.
Publicado: (2020)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_73appr74ft9tr73i961tagd7no